# Conversion of Tislelizumab Combined With Chemotherapy in Unresectable Esophageal Squamous Cell Carcinoma

> **NCT05449483** · PHASE2 · UNKNOWN · sponsor: **Tianjin Medical University Cancer Institute and Hospital** · enrollment: 40 (estimated)

## Conditions studied

- Esophageal Squamous Cell Carcinoma by AJCC V8 Stage
- Unresectable

## Interventions

- **DRUG:** tislelizumab+ Paclitaxel + Cisplatin

## Key facts

- **NCT ID:** NCT05449483
- **Lead sponsor:** Tianjin Medical University Cancer Institute and Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-05-11
- **Primary completion:** 2023-06-30
- **Final completion:** 2025-06-30
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2022-07-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05449483

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05449483, "Conversion of Tislelizumab Combined With Chemotherapy in Unresectable Esophageal Squamous Cell Carcinoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05449483. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*